The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is an impressive early mover in the rapidly growing psilocybin mushroom market
The next great investing boom is already underway…
And for investors, this opportunity could be just like investing in cannabis back in 2013.
The psilocybin mushroom market right now stands poised for explosive potential growth thanks to three critical factors:
1) A growing push toward legalization, with California and Colorado leading the way in the United States…
2) Mounting scientific evidence showing the health benefits of psilocybin mushrooms, including the potential to help treat serious illnesses…
3) An increasing awareness in the mainstream media – including films, books and media personalities – of the potential health benefits associated with psilocybin mushrooms, which is helping bring nationwide legalization closer to reality.
One company has quickly established itself as an early mover – and a potential market leader – in the rapidly-growing psilocybin mushroom market, offering investors a unique opportunity for high upside potential.
That company is The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3).
The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is a vertically integrated company that develops, licenses and sells plant-based products and formulas and conducts research into plant-based medicine in the $4.2 trillion global wellness market.
To build on its success in this market with legal hemp and cannabis markets, The Yield Growth Corp. is now aggressively pursuing research and market opportunities in the psilocybin mushroom market.
Widespread North American Movement Underway to Decriminalize Psychedelic Mushrooms
According to the Financial Post, cannabis legalization has set a strong precedent for magic mushrooms.
In May 2019, Denver, Colorado voted to decriminalize mushrooms that contain psilocybin, and Oakland California did the same a few weeks later. The state of Oregon is working to do the same for 2020.i
And in October 2019, the U.S. FDA granted “breakthrough therapy” status to a London-based company to test psilocybin for treatment-resistant depression.
This trend toward legalization is growing rapidly: Vice reports that there is a growing lobby dedicated to advocating for psychedelics – and that they are well-organized and well-funded.iii
Of course, this growing legalization movement is happening for good reason…
Psilocybin Mushrooms Have Shown the Potential for Significant Health Benefits
The health results that have been achieved worldwide with the support of psychedelics have caused a growing number of people to take notice.
Anecdotal evidence linking psilocybin to potential treatments for serious diseases goes back centuries.
And now modern science is confirming a number of important health benefits that have triggered explosive growth in the market.
For example, researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.iv
And studies have shown that psilocybin could provide effective treatment for things like depression, alcohol addiction and many other psychological disorders.
- Johns Hopkins Medicine recently announced the launch of a Center for Psychedelic and Consciousness Research, with $17 million in capital earmarked for studying psychedelics.
- That announcement from Johns Hopkins came on the heels of Imperial College London’s launch of a similar center backed by $3.5 million in private donations.
- And the University of Toronto has opened its Centre for Psychedelic Studies, which will host the world’s first clinical trials on microdosing psilocybin.v
A Closer Look at the Investment Potential in the Psilocybin Mushroom Market
Here’s why the increase of science-backed evidence supporting the health benefits of psilocybin mushrooms offers a high-upside investment opportunity:
The global antidepressant drug market was valued at $13.7 billion in 2016 and is projected to grow to $15.9 billion by 2023.
One hundred million of those diagnosed with major depressive disorder (MDD) are said to suffer from treatment-resistant depression (TRD). This accounts for approximately 33% of MDD cases.vi
The FDA decision to fast track the testing of psilocybin could allow for psychedelic mushrooms to penetrate this market.
Psychedelic mushrooms represent an exciting new opportunity for companies that can capitalize on cutting edge science and technology.
That makes the steps The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) has already taken critically important, as the company works to become among the first publicly traded companies to establish legal production and distribution of psilocybin for medical research.
The Yield Growth Corp. Has Moved Quickly to Seize this Opportunity
The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) has taken several significant steps to establish an early leadership position in the rapdly-growing psilocybin mushroom market, including establishing a new subsidiary – Flourish Mushroom Labs, Inc. – that is focused exclusively on the opportunity in both psychedelic and edible mushrooms.
Flourish Mushroom Labs aims to legally and safely commercialize psilocybin (magic) mushrooms and is tasked with becoming a leader in the modern renaissance of natural medicine.
Flourish has already achieved several key milestones, including:
- Filing a U.S. provisional patent application for the use of psychedelic mushroom actives for weight loss. Anticipated benefits include reduced food cravings, counteracting compulsive overeating, and aiding in improving quality of diet by altering food choices.
- Entering into a binding letter of intent with Acres Agricultural Canada Corp. to jointly form a company in Saint Vincent and the Grenadines to build a laboratory for the cultivation of and research and development into compounds and therapeutic use of psychedelic mushrooms.
- Acquired approximately 18% of Translational Life Sciences Inc., which aims to develop proprietary formulations using restricted substances to focus on unmet medical needs in opioid dependence, psychotic illness, pain management and traumatic brain injury, including concussion. The company also offers services to design and oversee clinical trials of restricted substances such as psilocybin based formulations for third parties.
The Translational Life Sciences team is comprised of physicians and scientists who are recognized thought leaders in the fields of Neurology, Pharmacology, Pain Management, Addiction and Biochemistry and have significant experience in the clinical application of cannabinoid compounds.
These moves appear to be just the beginning of the steps The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is taking in order to establish a strong early presence in the rapidly growing psilocybin mushroom space.
More than Mushrooms: The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3); is at the Forefront of the Cannabis-Infused Luxury Wellness Space
In addition to its recent advances in the psilocybin mushroom space, The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) has already established itself as a fully-integrated leader in the global wellness market.
The company is a leader in bringing hemp and cannabis-infused products to the cannabis-infused luxury wellness market in a way that connects ancient healing with modern science.
The Yield Growth Corp. has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It has filed 13 patents to protect its extraction methods and formulas. Yield Growth earns revenue through multiple streams including licensing, services and product sales.
By bringing cannabis to the luxury wellness market, The Yield Growth Corp. is serving a market filled with mainstream luxury consumers in search of sophisticated wellness products.
The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is a vertically-integrated company that currently has access to multiple revenue streams via its subsidiary companies, including:
Urban Juve Provisions, Inc.
- Direct to consumer sales within Canada and the U.S. via e-commerce site
- Retail distribution agreements with more than 110 brick and mortar stores across North America since the beginning of 2019
Wright & Well Essentials Inc.
- Now launching 9 THC products into the Oregon market under the brand Wright & Well
Wright & Well Manufacturing Inc.
- Legal U.S. retail and e-commerce distribution channel for beauty, health and wellness brands with legal hemp and CBD products for distribution throughout the United States, Europe and South America
UJ Beverages Inc.
- Line of eight wellness beverage formulas to be infused with CBD and THC and one capsule product intended to treat hangovers
Yield Botanicals Inc.
- Proprietary patent pending extraction technology combining Ayurveda therapeutic extraction methods with modern science and commercial hemp root oil production
Thrive Activations Inc.
- Provides management personnel and expertise to small and growing companies
The Yield Growth Corp. Well-Positioned to Deliver High Upside Potential to Investors
Investors looking to take advantage of the opportunities created by cannabis legalization in the global wellness industry – as well as the rapidly-growing psilocybin mushroom space – should consider adding shares of The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) while the company is still below Wall Street’s radar.
Just recently, the Company announced that it had achieved record quarterly revenue in the third quarter of 2019, increasing by 61% to $1.9 million in Q3 2019 compared to $1.2 million in Q2 2019, and increasing by 355% compared to $0.4 million in Q3 2018.
Beginning in Q2 2018, the company has achieved steady growth in revenues over the past 6 quarters:
Net losses decreased by 55% to $1.9 million in Q3 2019 compared to $4.1 million in Q2 2019, and decreased by 50% compared to $3.7 million in Q3 2018.
The company’s most current financial and operational results are available for review on the Company’s SEDAR profile at www.sedar.com.
With potentially explosive industry growth, a “Hall of Fame” level management team of experienced executives and a significant first-to-market advantage, The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) has the potential for exponential growth.
Dynamic, Proven Management Team Positions The Yield Growth Corp. for Success
The Yield Growth Corp’s highly experienced leadership team is made up of proven leaders with extensive backgrounds and success stories from a variety of relevant industries, including…
Co-Founder, President & CEO, Director
Penny is a serial entrepreneur and securities lawyer with over two decades of experience in online music, international film distribution, mobile payments, blockchain technology, crowdsourcing, renewable energy, pharmaceuticals, e-commerce and cannabis.
She is also co-founder of Merus Labs Inc. (TSX:MSL, NASDAQ:MSLI-Q), which was acquired by Norgine B.V. in 2017 for $342 million.
Penny was recognized in PROFIT Magazine’s W100 most successful entrepreneurs and included in PROFIT 500 Fastest Growing companies in 2015 and 2016.
Chief Operating Officer, The Yield Growth Corp.
Among her career achievements, Tamara was instrumental in the growth of Canadian fashion retailer Aritzia (TSX:ATZ) as its Vice President, Corporate Operations and Executive Vice President, People & Culture. When she joined in 2001, Aritzia had 10 stores and 30 head office employees, and Melck built several of the corporate backend functions from scratch, helping Aritzia to scale its operations and achieve $743M in annual revenue and to reach a market capitalization of over $1 billion when she left in 2017.
Melck was a member and former chair of the Executive Committee of Aritzia, and she directly led and oversaw numerous departmental and cross-functional projects of all sizes to build the necessary infrastructure to enable growth. Aritzia is a vertically integrated, innovative design house of exclusive fashion brands. It reported net revenue of $743.3 million in Fiscal 2018.
Jeff B. Smith
Chairman of the Advisory Board, The Yield Growth Corp.
Jeff Smith was the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies, the world’s largest and most diversified healthcare company with worldwide sales of US$76 billion in 2017.
In his most recent role as Johnson & Johnson Company Group Chairman for Consumer North America, Jeff delivered strong organic growth, new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several important strategic acquisitions including Vogue International LLC, La Lumière, and Neostrata. His division represented more than 42% of global revenue, delivering over US$6.5 billion in annual revenue with mid-single digit growth rates; spent over US$1 billion in marketing investment; delivered consistent market share gains and doubled the regional profitability. Jeff was on the Johnson & Johnson’s Group Operating Committee Executive.
Prior to acting as Chairman of Johnson & Johnson, in 2011 Jeff was appointed President, U.S. Skincare in the newly formed North American region. Jeff had full P&L responsibility for the Baby (JOHNSON’S®, AVEENO®) and Beauty Care divisions (NEUTROGENA®, AVEENO®, CLEAN & CLEAR®, LUBRIDERM® and KORRES® Natural products) within the United States. As President of Johnson & Johnson’s largest business unit, Jeff grew it from the third-largest skincare company to #1 in the U.S. over 3.5 years.
Vice President Licensing & General Counsel, The Yield Growth Corp.
Amy Frankel has over 15 years of experience working with consumer product companies. In her various roles as in-house counsel, Amy has gained vast experience building, protecting and expanding international brands. Previously, Amy was Co-General Counsel of Aritzia LP (TSX: ATZ) and Associate General Counsel of Skechers USA Inc. (NYSE: SKX). During her time at Skechers, annual revenues increased approximately 50% ($675M to $1.006B) and the share price increased over 300%. During her time at Aritzia, annual revenues increased approximately 100%, from under $400M to $743M. Her expertise includes negotiating inbound and outbound licensing deals, developing intellectual property strategies, and managing international intellectual property portfolios. Amy’s experience also includes corporate governance for private and public US and Canadian companies, as well as a wide breadth of commercial matters, including distribution agreements and technology contracts.
Amy began her career as a business litigator in Los Angeles, appearing before numerous state and federal courts before moving in-house with Skechers. Amy practiced law in California for 10 years prior to moving to Vancouver, BC. In 2008, she was admitted to the Law Society of British Columbia. Amy obtained her Bachelor’s degree from the University of California, Santa Barbara and her Juris Doctorate from the University of California, Hastings. She is licensed in California and British Columbia.
CFO, The Yield Growth Corp.
Rick Huang served as CFO of Hanwei Energy Services corporation (TSX: HE). Rick has also served as CFO of several other publicly traded companies, where he has managed all aspects of finance, banking, compliance, accounting, reporting, internal control, admin, and supporting the board of directors in financial oversight. He also has supervised all aspects of accounting for various subsidiary companies in Canada, China, Russia and Kazakhstan and consolidations under IFRS.
He has worked on investor relations activities, roadshow AGM preparations, and licensing agreements and has led various public equity financing projects raising funds of up to $90 million and leading acquisitions of up to $80 million. Rick has negotiated for international joint ventures, including drafting shareholders’ agreements, establishing international legal entities, and assets transfers. Rick also serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM) and previously Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD)
Disclaimer: This release/advertorial is a commercial advertisement prepared by DF Media (owner and publisher of Marijuanastox.com) and Winning Media LLC. (media placement company) and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. Winning Media and DF Media, with the website MarijuanaStox.com ,make no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for by The Yield Growth Corp. in an effort to enhance public awareness of The Yield Growth Corp. and its securities. Winning Media has received a cash budget by The Yield Growth Corp. for the sum total of one hundred thousand dollars cash as a total production budget for this advertising effort. Neither Marijuanastox.com or Winning Media currently holds the securities of The Yield Growth Corp. and does not currently intend to purchase such securities. This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words believe(s) anticipate(s), plan(s), expect(s) ,project(s) will make told and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934 and Canadian securities law. Further, this document includes statements regarding business, financing, business trends, future operating revenues and expenses and there can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuers actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as expects, will, anticipates, estimates, believes, may, or by statements indicating certain actions may, could, or might occur. More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at The Yield Growth Corp.’s Website and on SEDAR. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this advertorial. Furthermore, the CSE has not reviewed, approved or disapproved the contents of this advertorial. Winning Media and MarijuanaStox.com are not certified financial analysts or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.